NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Another week of interesting news! Most notably CS Medica partnered with a new distributor in Jordan, Curasight’s subscription period for the rights issue started, Genmab received new price targets, while Evaxion Biotech, Saniona, and Zealand Pharma had exciting pipeline development. More companies have yet to announce their 2023 results.

9 of the 20 companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Y-mAbs Therapeutics is still the best-performing Danish healthcare stock year-to-date with a 142% return and PharmaLundensis AB was the best Nordic investment last week. The Nordic sector is again in a negative trajectory.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you to invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Acarix

No news the past week

Ascendis Pharma

No news the past week

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

CS MEDICA A/S Partners with New Distributor to Launch CANNASEN® into Jordan (Link)

Curasight

Curasight released its annual report for 2023 (Link)

Curasight also published information memorandum in connection with forthcoming rights issue (Link)

The subscription period for the rights issue began on February 23 and runs until March 7.

Evaxion Biotech

Evaxion Announces Successful Completion of the Initial Phases of Ongoing Vaccine Collaboration with MSD (Link)

ExpreS2ion

ExpreS2ion’s Associated Company AdaptVac Receives Milestone Payment Following Completion of Bavarian Nordic’s Clinical Phase III Study for the COVID-19 Vaccine (Link)

Fluoguide

FluoGuide A/S issues warrants to CFO (Link)

Genmab

Genmab got new price targets last week of DKK 2400 from RBC and DKK 2119 from Cowen. The stock currently trades at 2020 DKK.

Gubra

No news the past week

Initiator Pharma

MAC Clinical Research converts its receivable into shares in Initiator Pharma (Link)

Initiator Pharma also released their Year-end report of 2023 (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

Saniona and Boehringer Ingelheim (BI) make molecules from previous collaboration available for BI´s Open Innovation platform (Link)

Scandion Oncology

Scandion Oncology will publish its Q4 results on February 28, 2024

SynAct Pharma

SynAct Pharma AB today publishes the fourth quarter and annual results of 2023 (Link)

ViroGates

No news the past week

Zealand Pharma

Zealand Pharma will publish its Q4 results on February 27 2024.

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis (Link)

Y-mAbs Therapeutics

Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024 (Links)

2cureX

2Curex publishes interim report for the fourth quarter and full year of 2023 and financial and strategic outlook for 2024 (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of -1,4%. The most notable news was CS Medica partnering with a new distributor in Jordan, the subscription period for Curasight’s rights issue starting, Genmab with new price targets, pipeline development for Evaxion together with MSD, Saniona and Boehringer Ingelheim making molecules, and Zealand Pharma delivering interesting phase 2 data for a drug against MASH with Boehringer Ingelheim. The best stocks year-to-date are Y-mAbs Therapeutics, CS Medica, and Expres2ion Biotech Holding with 49-142% increases after eight weeks of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 6.4%. Acarix was included in the list this week.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) fell 2.1% to 60.91. The index was previously recovering from the all-time low in October of 57.12 but is now on a downward trajectory again. In the past 12 months, it has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down more than 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

36-114% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

PharmaLundensis AB (114%) (Nordnet) main focus is on the treatment of severe pulmonary diseases. The three diseases the company is specialised in include chronic obstructive pulmonary disease (COPD), chronic bronchitis, and influenza-induced lung failure. In addition, development is made on system that eliminates the release of pharmaceutical pollution

Diamyd Medical AB (48%) (Nordnet) develops the diabetes vaccine Diamyd® with the active ingredient GAD, which has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure type 1 diabetes and other forms of diabetes. Diamyd Medical has independently pursued the development of the diabetes vaccine Diamyd® to global Phase III trial.

S2 Medical AB (34%) (Nordnet) is focused on the research and development of various wound healing products. Products that are offered include cellulose-based materials and dressings for healing burns, as well as chronic wounds. The products are sold under several brands, mainly in Europe.

Sources: Refinitiv & Nordnet